Sotagliflozin versus dapagliflozin to improve outcome of patients with diabetes and worsening heart failure: a cost per outcome analysis

@gcfmd @DrSiyabMD @djc795 @GreggWStone https://t.co/Ws0BgPy8LA

@SJGreene_md @DukeCardFellows @vkittipibul @DCRINews @mvaduganathan Sotagliflozin vs Dapa Sota NNT of 4 (95% CI 3-7) to prevent one event compared to Dapa’s NNT of 23 (95% CI 16-55). The cost per prevented event for Sota is below $27,260, while Dapa’s cost

@TheLipidGuy Sotagliflozin vs Dapa Sota NNT of 4 (95% CI 3-7) to prevent one event compared to Dapa’s NNT of 23 (95% CI 16-55). The cost per prevented event for Sota is below $27,260, while Dapa’s cost is significantly higher at $109,043 (95% CI $75,856-$2

Sotagliflozin is less favorable than other SGLT2i in the insurance coverage progression, but cost analysis by CNT&NNT is also worth considering. Sotagliflozin versus dapagliflozin to improve outcome of patients with diabetes and worsening heart failur